BPC-157: What Is Actually Known About the "Regenerative Peptide" — and What Isn't

BPC-157 (body protection compound-157) is a synthetic peptide of 15 amino acids, developed based on a fragment of a protein naturally found in human gastric juice. Since the 1990s, researchers in Croatia, mainly a team led by Predrag Sikirić, have published dozens of papers showing that when administered to animals, BPC-157 accelerates the healing of tendons, ligaments, muscles, and even the gastric and intestinal mucosa.

It's precisely this extensive animal literature — pointing to multidirectional effects: pro-angiogenic (stimulating new blood vessel formation), anti-inflammatory, and supportive of the migration of cells involved in tissue repair — that became the foundation of BPC-157's popularity in the biohacking and elite sports communities. The problem is that this popularity outpaced human evidence by decades, not years.

It's worth noting the scale of the disparity: a 2025 systematic review, analyzing BPC-157 literature from 1993-2024, identified a total of 36 publications, of which only one concerned a clinical study in humans, while the remaining 35 were preclinical works (animals, cell cultures). That's not a small edge in animal evidence — it's an almost complete absence of clinical verification.

Theoretical safety concerns raised in the review literature include the risk of pathological angiogenesis (relevant especially for people with a cancer history, where enhanced blood vessel formation could theoretically favor tumor growth), excessive nitric oxide production, and unpredictable effects on the metabolism of other medications taken. Preclinical studies haven't yet identified a clear toxicity threshold, but that's not the same as confirming long-term safety in humans.

The lack of large clinical trials on BPC-157 isn't accidental or the result of 'hiding evidence,' as some conspiracy theories circulating on social media suggest. Substances that aren't patent-protected and aren't registered as drugs rarely undergo costly, multi-year phase III trials, because no commercial entity has sufficient financial incentive to fund them — the cost of such trials runs into tens of millions of dollars, and without patent protection it's hard to recoup that investment.

This phenomenon, sometimes called an 'evidence gap' rather than a 'conspiracy of silence,' affects many mechanistically promising substances outside the mainstream pharmaceutical industry. That doesn't change the practical outcome for a consumer, though: a lack of reliable human safety and efficacy data, regardless of the reason for that gap.

BPC-157 is a good example of how a promising biological mechanism and a large volume of animal research can create an impression of far stronger scientific knowledge than actually exists. Fascinating molecular biology isn't the same as clinical proof — and in this particular case, the gap between the two is unusually wide, even by the standards of supplementation and biohacking, where evidence gaps are common. Anyone considering this substance should be aware they're opting for something closer to participating in an uncontrolled self-experiment than using a proven therapy.